Capital Research Global Investors Vertex Pharmaceuticals Inc Transaction History
Capital Research Global Investors
- $428 Billion
- Q1 2024
A detailed history of Capital Research Global Investors transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Capital Research Global Investors holds 5,743,882 shares of VRTX stock, worth $2.62 Billion. This represents 0.56% of its overall portfolio holdings.
Number of Shares
5,743,882
Previous 3,567,664
61.0%
Holding current value
$2.62 Billion
Previous $1.45 Billion
65.4%
% of portfolio
0.56%
Previous 0.37%
Shares
15 transactions
Others Institutions Holding VRTX
# of Institutions
1,623Shares Held
222MCall Options Held
1.35MPut Options Held
1.49M-
Capital World Investors Los Angeles, CA25.6MShares$11.6 Billion1.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA22.7MShares$10.3 Billion0.19% of portfolio
-
Black Rock Inc. New York, NY22MShares$10 Billion0.22% of portfolio
-
State Street Corp Boston, MA12MShares$5.47 Billion0.23% of portfolio
-
Alliancebernstein L.P. New York, NY7.1MShares$3.23 Billion1.08% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $117B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...